Cardinal Health price target raised to $52 from $50 at RW Baird Baird raised its price target on Cardinal Health following Q1 results. The firm cited earnings leverage, continued generics contributions, growth in platforms outside of drug distribution, and share repurchases. Shares are Outperform rated.
Cardinal Health raises FY16 non-GAAP EPS to $4.85-$5.05 from $4.28-$4.38 FY16 EPS consensus of $4.37. The updated guidance is due to strong FY15 performance momentum it carried into FY16. It expects financial performance to be weighted towards 2H16.